Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 39 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
bb2121 for Relapsed and Refractory Multiple Myeloma	Idecabtagene vicleucel (Ide-cel; bb2121)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2018	View \| Download
Belantamab mafodotin for relapsed / refractory multiple myeloma – Fourth line	Belantamab mafodotin (GSK2857916; anti-BCMA-ADC)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2019	View \| Download
Belantamab mafodotin for treating relapsed or refractory multiple myeloma	Belantamab mafodotin (GSK2857916; anti-BCMA-ADC)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2022	View \| Download
Belantamab mafodotin with bortezomib and dexamethasone for previously treated relapsed/refractory multiple myeloma	Belantamab mafodotin (GSK2857916; anti-BCMA-ADC) , Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2022	View \| Download
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated relapsed/refractory multiple myeloma	Belantamab mafodotin (GSK2857916; anti-BCMA-ADC) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Pomalidomide (Imnovid; CC-4047; Pomalyst)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2022	View \| Download
Carfilzomib in addition to daratumumab and dexamethasone for relapsed and/or refractory multiple myeloma	Carfilzomib (Kyprolis; ONO-7057) , Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2019	View \| Download
Ciltacabtagene autoleucel for relapsed and refractory multiple myeloma	Ciltacabtagene Autoleucel (JNJ-68284528; LCAR-B38M CAR-T cell therapy; LCAR-B38M; JNJ 4528)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas , Haematology	2021	View \| Download
Daratumumab (Darzalex) with lenalidomide and dexamethasone for multiple myeloma – first line	Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Lenalidomide (Revlimid)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2017	View \| Download
Daratumumab (subcutaneous injection) for multiple myeloma	Daratumumab (Darzalex; JNJ-54767414)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2019	View \| Download
Daratumumab for the treating high-risk smouldering multiple myeloma	Daratumumab (Darzalex; JNJ-54767414)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2022	View \| Download